Sosei Heptares and AbbVie enter into new multi-target collaboration to discover, develop and commercialize novel drugs targeting neurological diseases

Sosei Group Company

  • New Strategic Collaboration Leverages Sosei Heptares’ StaR® AbbVie’s SBDD technology and platform and extensive neuroscience expertise

  • Second collaboration with AbbVie follows 2020 deal focused on inflammatory and autoimmune diseases

  • Sosei Heptares is eligible to receive up to $80 million in upfront and short-term milestone payments and has the potential to receive further downline payments totaling up to $1.2 billion, plus royalties staggered

TOKYO, Japan and CAMBRIDGE, UK, Aug. 02, 2022 (GLOBE NEWSWIRE) — Sosei Group Corporation (“the Company”; TSE:4565) and AbbVie (NYSE:ABBV), a global research-based biopharmaceutical company, announce they have entered into a new drug discovery collaboration and license option agreement to discover, develop and commercialize small molecules that modulate novel G-protein-coupled receptor (GPCR) targets associated with neurological diseases.

The new deal will leverage Sosei Heptares’ StaR® the technology and structure-based drug design (SBDD) platform and AbbVie’s extensive expertise in neuroscience and disease. The agreement expands the scope of the ongoing collaboration between Sosei Heptares and AbbVie, building on the first multi-target discovery agreement signed between the companies in June 2020, which focuses on the areas of inflammatory and autonomic diseases. -immune.

Under the terms of the new agreement, Sosei Heptares will conduct and fund R&D activities through the completion of Enabling Investigational New Drug (IND) studies. AbbVie has the exclusive option to license up to three programs at this stage and will be responsible for clinical, regulatory and commercial development thereafter. Sosei Heptares receives an upfront payment of US$40 million upon signing and is eligible to receive up to US$40 million in planned short-term research milestone payments over the next three years, as well as potential further option, development and commercial milestones totaling up to US$1.2 billion, plus tiered royalties on worldwide sales.

Matt Barnes, UK Research and Development Manager, Sosei Heptares, said: “We are excited to enter into this new multi-target discovery collaboration with AbbVie in neuroscience, a therapeutic area in which we share deep and complementary experience and expertise. We have established a very productive working relationship with our counterparts at AbbVie over the past two years through our initial collaboration and are very pleased with how this is progressing. We believe this strong foundation will allow us to get off to a quick start as we tackle the new and ambitious neurological goals under this new agreement.

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new drugs based on our proprietary GPCR-targeted StaR.® technology and structure based drug design platform capabilities. We are developing a broad and deep pipeline of new drugs in multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s largest pharmaceutical companies and many emerging technology companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan, with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the trademark and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are registered trademarks of Sosei Group companies.

For more information, visit https://soseiheptares.com/
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Requests:
Sosei Heptares – Media and investor relations
Hironoshin Nomura, CFO
Shinichiro Nishishita, Vice President of Investor Relations, Head of Regulatory Disclosures
Candelle Chong, Senior Vice President of Investor Relations and Corporate Strategy
Japan: +81 (0)3 5210 3399 | UK: +44 (0)1223 949390 | [email protected]

MEDiSTRAVA Consulting (for international media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0)203 928 6900| [email protected]

Forward-Looking Statements of Sosei Heptares
This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. A variety of risks could cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; the inability to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; reliance on strategic alliance partners to develop and market products and services; difficulties or delays in obtaining regulatory approvals to commercialize products and services resulting from development efforts; the requirement for substantial funding to conduct research and development activities and to expand commercialization activities; and product initiatives by competitors. Due to these factors, potential investors are cautioned not to rely on forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Emilie Brandow

Check Also

Trigon Terminals Set to Nearly Double Terminal Capacity and Advance Green Diversification with New Federal Funding

PRINCE RUPERT, BC, November 16, 2022 /CNW/ – Prince Rupert Trigon Pacific Terminals Limited (Trigon) …